InspireMD (NSPR) AI Stock Analysis

• Market Cap: $89.83M
• Dividend Yield: N/A
• Average Volume (3M): 102.59K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.09
• Revenue Growth: 14.04%
• EPS Growth: -0.65%
• Country: US
• Employees: 85
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.17
• Shares Outstanding: 42,370,995
• 10 Day Avg. Volume: 68,719
• 30 Day Avg. Volume: 102,589
• PEG Ratio: 0.47
• Price to Book (P/B): 3.06
• Price to Sales (P/S): 15.73
• P/FCF Ratio: -4.74
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: 12.83
• Enterprise Value/Gross Profit: 51.51
• Enterprise Value/Ebitda: -2.16
• 1Y Price Target: $5.00
• Price Target Upside: 132.56% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $2.00 ▼(-6.98% Downside)

InspireMD's overall stock score is primarily impacted by its financial performance, which shows revenue growth but significant profitability and cash flow challenges. The technical analysis indicates a bearish trend, while valuation metrics are weak due to ongoing losses. The earnings call provided some positive insights with revenue growth and improved margins, but these are offset by increased expenses and net losses.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand and successful product adoption, particularly with the U.S. launch of CGuard Prime, enhancing long-term business prospects.

Gross Margin Improvement

Improved gross margins reflect better cost management and operational efficiency, which can lead to enhanced profitability and financial health over time.

Clinical Validation

The publication of CREST-2 data strengthens the clinical credibility of InspireMD's stent technology, potentially increasing adoption and market penetration in the long term.

Negative Factors

Net Loss Increase

The increasing net loss highlights ongoing financial challenges, which may affect the company's ability to invest in growth and innovation, potentially impacting future performance.

Cash Flow Challenges

Negative cash flow indicates liquidity issues, which could constrain InspireMD's operational flexibility and ability to fund strategic initiatives, affecting long-term sustainability.

Increase in Operating Expenses

Rising operating expenses can erode profitability and strain financial resources, potentially limiting the company's ability to achieve sustainable growth and maintain competitive advantage.

InspireMD Business Overview & Revenue Model

Company Description

InspireMD, Inc. is a medical technology company focused on transforming the treatment of cardiovascular disease. The company specializes in developing and commercializing innovative solutions for coronary artery disease, particularly its proprietary MGuard technology, which incorporates a unique mesh design to enhance the safety and efficacy of vascular interventions. InspireMD operates primarily in the healthcare sector, targeting hospitals and medical professionals who require advanced tools for the treatment of patients with complex coronary conditions.

How the Company Makes Money

InspireMD generates revenue through the sale of its MGuard stent products to hospitals and healthcare providers. The company employs a direct sales model and also engages distributors to expand its market reach. Key revenue streams include product sales, which are driven by the volume of procedures performed using their stents. Additionally, InspireMD may benefit from strategic partnerships with medical institutions and research organizations that facilitate clinical studies and product validation, potentially leading to increased adoption of their technologies. The company may also explore licensing agreements or collaborations that can enhance its product offerings and broaden its market presence.

InspireMD Financial Statement Overview

Summary

InspireMD shows revenue growth but faces significant profitability and cash flow challenges. The company maintains a strong equity position, yet ongoing operational losses and negative cash flows pose risks. Improvements in operational efficiency and cost management are essential.

Income Statement

InspireMD has shown a consistent increase in revenue over the years, with a revenue growth rate of 12.95% from 2023 to 2024. However, the company struggles with profitability as indicated by its negative net profit margin of 22.22% in 2024 and a negative EBIT margin of 47.79%. The consistent negative EBITDA margin suggests ongoing operational challenges.

Balance Sheet

The company's balance sheet reflects a solid equity position with an equity ratio of 77.06% in 2024, indicating financial stability. However, the high debt-to-equity ratio of 0.05 suggests a manageable but present level of leverage. Return on equity is positive at 4.31% for 2024, indicating some profitability despite overall losses.

Cash Flow

InspireMD's cash flow statement reveals challenges in generating positive cash flows, with a significant negative free cash flow in 2024. The operating cash flow to net income ratio is negative, indicating issues in translating income into cash. The free cash flow to net income ratio is also negative, further emphasizing liquidity concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.78M	7.01M	6.21M	5.17M	4.50M	2.48M
Gross Profit	1.94M	1.51M	1.81M	1.12M	754.00K	83.00K
EBITDA	-46.17M	-33.22M	-20.91M	-18.52M	-14.55M	-10.23M
Net Income	-46.20M	-32.01M	-19.92M	-18.49M	-14.92M	-10.54M
Balance Sheet
Total Assets	78.47M	46.81M	47.64M	24.65M	39.71M	17.78M
Cash, Cash Equivalents and Short-Term Investments	63.40M	34.64M	39.02M	17.80M	34.04M	12.64M
Total Debt	2.37M	2.34M	1.59M	1.61M	1.20M	1.40M
Total Liabilities	14.36M	10.72M	8.14M	7.26M	6.18M	5.61M
Stockholders Equity	64.11M	36.09M	39.50M	17.39M	33.53M	12.16M
Cash Flow
Free Cash Flow	-34.08M	-23.27M	-16.76M	-16.02M	-13.55M	-9.17M
Operating Cash Flow	-32.51M	-21.87M	-16.38M	-15.54M	-13.21M	-9.08M
Investing Cash Flow	22.82M	12.64M	-16.09M	8.44M	-22.46M	-187.00K
Financing Cash Flow	57.13M	18.45M	37.53M	-140.00K	35.03M	16.39M

InspireMD Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.15
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NSPR, the sentiment is Positive. The current price of 2.15 is above the 20-day moving average (MA) of 1.96, above the 50-day MA of 2.04, and below the 200-day MA of 2.38, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 61.03 is Neutral, neither overbought nor oversold. The STOCH value of 87.79 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NSPR.

InspireMD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XTNT	66 Neutral	$113.40M	76.47	3.64%	―	16.88%	―
APYX	60 Neutral	$148.12M	-9.88	-172.18%	―	-1.32%	55.62%
EDAP	59 Neutral	$106.57M	-4.89	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANIK	49 Neutral	$135.85M	-4.12	-8.73%	―	-31.29%	65.68%
NSPR	46 Neutral	$89.83M	-2.55	-87.61%	―	14.04%	-0.65%
VANI	44 Neutral	$105.05M	-3.10	-265.02%	―	―	-0.27%

InspireMD Corporate Events

InspireMD Reports Record Q3 Revenue with U.S. Launch

On November 4, 2025, InspireMD reported its financial results for the third quarter of 2025, highlighting a successful initial U.S. commercial launch of its CGuard Prime carotid stent system, which contributed to a record quarterly revenue of $2.5 million, a 39% increase from the previous year. The company completed over 100 carotid procedures in the U.S. and strengthened its leadership team, signaling strong growth and demand for its solutions globally. Despite a net loss of $12.7 million for the quarter, the company is optimistic about its future growth, supported by $58 million in gross proceeds added to its balance sheet in July.

InspireMD Appoints Dan Dearen to Board of Directors

On September 17, 2025, InspireMD announced the appointment of Dan Dearen to its Board of Directors. With nearly 40 years of experience in the medical device and life sciences sectors, Dearen is expected to bring valuable financial expertise and strategic insight to the company. His appointment comes at a pivotal time as InspireMD continues the U.S. commercial launch of its CGuard Prime stent system, which has received FDA approval. This strategic move is anticipated to enhance InspireMD’s market position and support its growth ambitions in the carotid intervention market.